Who We Are

 Celtic Biotech is developing novel candidate therapies for the treatment of solid cancers and pain in humans. Derived from specialised receptor binding proteins found in snake venom, these product candidates have the potential to increase survival,  improve quality-of-life and reduce treatment costs for cancer patients.

Celtic Biotech is focusing its research on solid tumours, including non-small-cell lung cancer (NSCLC), as its initial targets.  The Company's lead candidate, CB24 (Crotoxin), has been observed to be highly toxic to various tumour cell lines in pre-clinical and early clinical studies.